“Immunosenescence” has been invoked as the root cause of increased incidence and severity of infectious disease in older adults and their poorer response to vaccination, and is implicated in increased solid cancers and increased autoimmunity with age. But how to define it in the individual and to show that immunosenescence is responsible for these adverse health outcomes? How can we monitor interventions aimed at restoring appropriate immune function to overcome these perceived immune deficits? Hence, the many efforts over the years aimed at establishing biomarkers of immunosenescence which to be useful must exhibit robust correlations with the chosen clinical outcome. Developments in “omics” technologies acquiring unprecedently detailed data on personal trajectories of immunosenescence and taking into account the under-appreciated importance of gender, ethnicity geography, socioeconomic, and multiple other differences will be of pivotal importance to identify biomarkers that are clinically useful at the level of the individual. This contribution addresses the question of whether or not we are currently in possession of any such useful biomarkers.
CITATION STYLE
Pawelec, G. (2020, October 1). The human immunosenescence phenotype: does it exist? Seminars in Immunopathology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00281-020-00810-3
Mendeley helps you to discover research relevant for your work.